Market Currents
A federal appeals court issues a mixed ruling for Myriad Genetics (MYGN -1%), reversing a lower...
-
Thursday, August 16, 2012, 1:17 PM ETA federal appeals court issues a mixed ruling for Myriad Genetics (MYGN -1%), reversing a lower court ruling which held that the drug developer's "isolated" DNA molecules aren't eligible for patents. However, the court also upholds the lower court's finding that MYGN's methods for comparing or analyzing DNA aren't eligible for patents. The company says it's still a win, as the gene patent claims were the meat of the case.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
